

Giuseppe Pelosi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9443677/publications.pdf>

Version: 2024-02-01

332
papers

19,446
citations

14655

66
h-index

14759

127
g-index

339
all docs

339
docs citations

339
times ranked

19233
citing authors

#	ARTICLE	IF	CITATIONS
1	To Do Is Better: Prompt Surgery Is Indicated in COVID-19 Patients With Complicated Pneumatocele. <i>Annals of Thoracic Surgery</i> , 2022, 113, 1390.	1.3	1
2	The Natural History in Lung Neuroendocrine Neoplasms: The Stone Guest Who Matters. <i>Journal of Thoracic Oncology</i> , 2022, 17, e5-e8.	1.1	3
3	Labeling Lung Neuroendocrine Neoplasms for Ki-67 Antigen to Score a Bull's-Eye, Not Shoot in the Dark. <i>Journal of Thoracic Oncology</i> , 2022, 17, e41-e44.	1.1	0
4	Utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e041961.	1.9	6
5	Surgical Resections of Superinfected Pneumatoceles in a COVID-19 Patient. <i>Annals of Thoracic Surgery</i> , 2021, 111, e23-e25.	1.3	19
6	Clinical implications of lung neuroendocrine neoplasm classification. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 377-387.	2.4	4
7	Morphologic and molecular classification of lung neuroendocrine neoplasms. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 5-19.	2.8	44
8	Primary MiNEN of the urinary bladder: an hitherto undescribed entity composed of large cell neuroendocrine carcinoma and adenocarcinoma with a distinct clinical behavior. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 69-78.	2.8	5
9	High-resolution CT in smoking-related interstitial lung diseases. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 106-112.	1.2	2
10	Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future. <i>ESMO Open</i> , 2021, 6, 100024.	4.5	13
11	Neuroendocrine neoplasms of the biliary tree, liver and pancreas: a pathological approach. <i>Pathologica</i> , 2021, 113, 28-38.	3.4	17
12	Molecular Pathology of Well-Differentiated Pulmonary and Thymic Neuroendocrine Tumors: What Do Pathologists Need to Know?. <i>Endocrine Pathology</i> , 2021, 32, 154-168.	9.0	25
13	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 686-696.	1.1	13
14	Improving Survival in Lymphangioleiomyomatosis: A 16-Year Observational Study in a Large Cohort of Patients. <i>Respiration</i> , 2021, 100, 989-999.	2.6	8
15	SMARCA2 Deficiency While Preserving SMARCA4 and SMARCB1 in Lung Neuroendocrine Carcinomas. <i>Journal of Thoracic Oncology</i> , 2021, 16, e32-e35.	1.1	2
16	Neuroendocrine neoplasms of the lung: a pathology update. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 381-385.	0.5	2
17	Aggressive early-stage lung adenocarcinoma is characterized by epithelial cell plasticity with acquirement of stem-like traits and immune evasion phenotype. <i>Oncogene</i> , 2021, 40, 4980-4991.	5.9	8
18	Over-Time Risk of Lung Cancer Is Largely Owing to Continuing Smoking Exposition: A Good Reason to Quit. <i>Journal of Thoracic Oncology</i> , 2021, 16, e57-e59.	1.1	3

#	ARTICLE	IF	CITATIONS
19	Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM). <i>ESMO Open</i> , 2021, 6, 100188.	4.5	10
20	Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms. <i>Cancers</i> , 2021, 13, 4875.	3.7	7
21	Coexpression of ^{18}F -Np63/p40 and TTF1 Within Most of the Same Individual Cells Identifies Life-Threatening NSCLC Featuring Squamous and Glandular Biphenotypic Differentiation: Clinicopathologic Correlations. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100222.	1.1	8
22	Recent advances and current controversies in lung neuroendocrine neoplasms. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 90-97.	1.5	7
23	Intratumor Distribution of Ki-67 Antigen Beyond Labeling Index for Clinical Decision-Making: A New Way of Counting. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100207.	1.1	1
24	Bcl-10, trypsin and synaptophysin helps recognize acinar cell and mixed acinar neuroendocrine cell carcinoma of the pancreas on both preoperative cytological samples and needle biopsy specimens. <i>Pathology Research and Practice</i> , 2021, 226, 153593.	2.3	9
25	A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors. <i>Endocrine Pathology</i> , 2021, 32, 396-407.	9.0	16
26	Thoracic (Lung/Thymus) Neuroendocrine Neoplasms. , 2021, , 151-206.		2
27	The Ki-67 antigen in the new 2021 World Health Organization classification of lung neuroendocrine neoplasms. <i>Pathologica</i> , 2021, 113, 377-387.	3.4	10
28	KEAP1 and TP53 (Co)mutation in Lung Adenocarcinoma: Another Bullet for Immunotherapy?. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1979-1983.	1.1	5
29	Parietal Pleura-Based Malignant Perivascular Epithelioid Cell Neoplasm Protruding Into Serous Cavity: A Hitherto Unrecognized Occurrence. <i>Journal of Thoracic Oncology</i> , 2020, 15, 462-466.	1.1	0
30	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 499-519.	1.1	203
31	The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based antihypertensive therapies. <i>Internal and Emergency Medicine</i> , 2020, 15, 1583-1584.	2.0	21
32	RE: Spread Through Air Spaces (STAS) is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2020, 15, e116-e117.	1.1	2
33	Distinguishing multiple lung primaries from intra-pulmonary metastases and treatment implications. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 985-995.	2.4	6
34	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	1.1	182
35	Immunohistochemical neuroendocrine marker expression in primary pulmonary NUT carcinoma: a diagnostic pitfall. <i>Histopathology</i> , 2020, 77, 508-510.	2.9	14
36	Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe. <i>Cancers</i> , 2020, 12, 1672.	3.7	50

#	ARTICLE	IF	CITATIONS
37	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1599-1610.	1.1	234
38	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 709-740.	1.1	205
39	Typical Carcinoid. <i>Encyclopedia of Pathology</i> , 2020, , 1-6.	0.0	0
40	Thymic Carcinoids (Typical and Atypical). <i>Encyclopedia of Pathology</i> , 2020, , 1-4.	0.0	0
41	Large Cell Neuroendocrine Carcinoma, Lung, Endocrine. <i>Encyclopedia of Pathology</i> , 2020, , 1-6.	0.0	0
42	Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. <i>Nature Communications</i> , 2019, 10, 3407.	12.8	132
43	Spread of hyperplastic pulmonary neuroendocrine cells into air spaces (S.H.I.P.M.E.N.T.S): A proof for artifact. <i>Lung Cancer</i> , 2019, 137, 43-47.	2.0	10
44	Giant Secondary Overgrowth of Type-1 Pulmonary Cystic Airway Malformation Upon Development of Anaplastic Lymphoma Kinase Rearranged Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2019-2022.	1.1	0
45	Lung Cryobiopsy for the Diagnosis of Interstitial Lung Diseases: A Series Contribution to a Debated Procedure. <i>Medicina (Lithuania)</i> , 2019, 55, 606.	2.0	13
46	Spindle Cell Nuclear in Testis Carcinoma of the Lung: A Challenging Tumor. <i>Journal of Thoracic Oncology</i> , 2019, 14, 311-313.	1.1	4
47	Molecular Classification of Neuroendocrine Tumors of the Thymus. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1472-1483.	1.1	53
48	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1651-1661.	1.1	73
49	Recent advances in the molecular landscape of lung neuroendocrine tumors. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 281-297.	3.1	38
50	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 377-407.	1.1	212
51	Ki-67 Evaluation for Clinical Decision in Metastatic Lung Carcinoids: A Proof of Concept. <i>BMC Clinical Pathology</i> , 2019, 12, 2632010X1982925.	1.7	24
52	The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e031531.	1.9	12
53	Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. <i>European Respiratory Review</i> , 2019, 28, 190044.	7.1	66
54	Pulmonary hypertension and chronic lung disease: where are we headed?. <i>European Respiratory Review</i> , 2019, 28, 190065.	7.1	19

#	ARTICLE	IF	CITATIONS
55	Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 464.	8.6	42
56	Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 567-577.	2.8	64
57	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. <i>Journal of Thoracic Oncology</i> , 2018, 13, 205-217.	1.1	33
58	Classification of Abdominal Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2018, , 21-32.	0.1	0
59	OA03.03 Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study. <i>Journal of Thoracic Oncology</i> , 2018, 13, S325.	1.1	13
60	Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1750-1761.	1.1	27
61	Angiogenin and the MMP9â€¦TIMP2 axis are upâ€¦regulated in proangiogenic, decidual NKâ€¦like cells from patients with colorectal cancer. <i>FASEB Journal</i> , 2018, 32, 5365-5377.	0.5	91
62	Serum Steroid Ratio Profiles in Prostate Cancer: A New Diagnostic Tool Toward a Personalized Medicine Approach. <i>Frontiers in Endocrinology</i> , 2018, 9, 110.	3.5	10
63	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1302-1311.	1.1	589
64	5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 16437-16450.	1.8	12
65	Sarcomatoid Carcinomas, Lung. <i>Encyclopedia of Pathology</i> , 2018, , 395-398.	0.0	0
66	Carcinosarcoma, Lung. <i>Encyclopedia of Pathology</i> , 2018, , 114-117.	0.0	0
67	Pathological Analysis of Abdominal Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2018, , 123-135.	0.1	0
68	Lung cancer screening with low-dose spiral computed tomography: evidence from a pooled analysis of two Italian randomized trials. <i>European Journal of Cancer Prevention</i> , 2017, 26, 324-329.	1.3	36
69	Pulmonary adenocarcinoma with mucin production modulates phenotype according to common genetic traits: a reappraisal of mucinous adenocarcinoma and colloid adenocarcinoma. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 139-151.	3.0	22
70	Thymus neuroendocrine tumors with CTNNB1 gene mutations, disarrayed Ñ-catenin expression, and dual intra-tumor Ki-67 labeling index compartmentalization challenge the concept of secondary high-grade neuroendocrine tumor: a paradigm shift. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 31-47.	2.8	31
71	Distinctive pathological and clinical features of lung carcinoids with high proliferation index. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 713-720.	2.8	64
72	Increased frequency of bronchiolar histotypes in lung carcinomas associated with idiopathic pulmonary fibrosis. <i>Histopathology</i> , 2017, 71, 725-735.	2.9	31

#	ARTICLE	IF	CITATIONS
73	Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 153-164.	2.8	67
74	The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. <i>Journal of Thoracic Oncology</i> , 2017, 12, 334-346.	1.1	113
75	Towards personalised medicine in lung and thymus neuroendocrine tumours. <i>Lancet Oncology</i> , The, 2017, 18, 1563-1565.	10.7	1
76	Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness. <i>Scientific Reports</i> , 2017, 7, 6689.	3.3	35
77	The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. <i>Human Pathology</i> , 2017, 67, 160-168.	2.0	50
78	Alpha-fetoprotein elevation in NUT midline carcinoma: a case report. <i>BMC Cancer</i> , 2017, 17, 266.	2.6	13
79	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin remodelling genes as major players and a prognostic role for <i>TERT</i> , <i>RB1</i> , <i>MEN1</i> and <i>KMT2D</i> . <i>Journal of Pathology</i> , 2017, 241, 488-500.	4.5	179
80	Uncommon Somatic Mutations in Metastatic NUT Midline Carcinoma. <i>Tumori</i> , 2017, 103, S5-S8.	1.1	10
81	Classification of pulmonary neuroendocrine tumors: new insights. <i>Translational Lung Cancer Research</i> , 2017, 6, 513-529.	2.8	104
82	The role of multimodal treatment in patients with advanced lung neuroendocrine tumors. <i>Journal of Thoracic Disease</i> , 2017, 9, S1501-S1510.	1.4	18
83	Grading lung neuroendocrine tumors: Controversies in search of a solution. <i>Histology and Histopathology</i> , 2017, 32, 223-241.	0.7	27
84	Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 651-662.	2.8	14
85	Diagnosis and management of typical and atypical lung carcinoids. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 167-176.	4.4	35
86	The impact of immunohistochemistry on the classification of lung tumors. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 1105-1121.	2.5	16
87	Applicability of Under Vacuum Fresh Tissue Sealing and Cooling to Omics Analysis of Tumor Tissues. <i>Biopreservation and Biobanking</i> , 2016, 14, 480-490.	1.0	10
88	Systemic Approach to Malignant Pleural Mesothelioma: What News of Chemotherapy, Targeted Agents and Immunotherapy?. <i>Tumori</i> , 2016, 102, 18-30.	1.1	8
89	209P: SMO mutation is a strong negative prognostic factor in malignant pleural mesothelioma. <i>Journal of Thoracic Oncology</i> , 2016, 11, S147.	1.1	0
90	Screening with Low-Dose Computed Tomography Does Not Improve Survival of Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 187-193.	1.1	41

#	ARTICLE	IF	CITATIONS
91	Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 451-461.	2.8	2
92	Conversion to stemâ€cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells. <i>Molecular Oncology</i> , 2016, 10, 253-271.	4.6	120
93	Clinical Response of Carcinomas Harboring the BRD4â€NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. <i>Cancer Discovery</i> , 2016, 6, 492-500.	9.4	319
94	Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants. <i>Journal of Thoracic Oncology</i> , 2016, 11, 693-699.	1.1	50
95	Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 718-728.	1.1	22
96	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. <i>Investigational New Drugs</i> , 2016, 34, 236-242.	2.6	21
97	Osteopontin, E-cadherin, and Î²-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 412-420.	5.3	37
98	Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1560-1569.	1.1	26
99	Challenging Lung Carcinoma with Coexistent Î³Np63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1500-1502.	1.1	20
100	New developments in the management of advanced melanoma – role of pembrolizumab. <i>OncoTargets and Therapy</i> , 2015, 8, 2535.	2.0	16
101	Germline polymorphisms and survival of lung adenocarcinoma patients: A genomeâ€wide study in two European patient series. <i>International Journal of Cancer</i> , 2015, 136, E262-71.	5.1	16
102	<i>EGFR</i>-Driven Behavior and Inpatient T790M Mutation Heterogeneity of Nonâ€Small-Cell Carcinoma With Squamous Histology. <i>Journal of Clinical Oncology</i> , 2015, 33, e115-e118.	1.6	14
103	What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 469-479.	1.5	27
104	The 2015 World Health Organization Classification of Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1243-1260.	1.1	3,313
105	Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. <i>Cancer Letters</i> , 2015, 359, 269-274.	7.2	9
106	Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient. <i>Lung Cancer</i> , 2015, 87, 204-206.	2.0	5
107	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. <i>Annals of Oncology</i> , 2015, 26, 1604-1620.	1.2	514
108	Gene Signatures Stratify Computed Tomography Screening Detected Lung Cancer in High-Risk Populations. <i>EBioMedicine</i> , 2015, 2, 831-840.	6.1	7

#	ARTICLE	IF	CITATIONS
109	Large cell carcinoma of the lung: A tumor in search of an author. A clinically oriented critical reappraisal. <i>Lung Cancer</i> , 2015, 87, 226-231.	2.0	39
110	Uterine Inflammatory Myofibroblastic Tumor in a 10-Year-Old Girl Presenting As Polypoid Mass. <i>Journal of Clinical Oncology</i> , 2015, 33, e7-e10.	1.6	22
111	Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. <i>Annals of Oncology</i> , 2015, 26, 838-847.	1.2	21
112	Inference on germline <i>BAP1</i> mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 51-62.	2.8	55
113	Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening. <i>Oncotarget</i> , 2015, 6, 32868-32877.	1.8	69
114	Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status. <i>PLoS ONE</i> , 2014, 9, e92147.	2.5	18
115	Therapeutic Biomarkers in Lung Neuroendocrine Neoplasia. <i>Endocrine Pathology</i> , 2014, 25, 371-377.	9.0	12
116	FOLFOX-4 Chemotherapy for Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma. <i>Oncologist</i> , 2014, 19, 845-850.	3.7	48
117	Gingival Metastasis as First Sign of Multiorgan Dissemination of Epithelioid Malignant Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1226-1229.	1.1	6
118	Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas. <i>International Journal of Surgical Pathology</i> , 2014, 22, 401-407.	0.8	14
119	Does Immunohistochemistry Affect Response to Therapy and Survival of Inoperable Non-Small Cell Lung Carcinoma Patients? A Survey of 145 Stage III-IV Consecutive Cases. <i>International Journal of Surgical Pathology</i> , 2014, 22, 136-148.	0.8	8
120	Ki-67 Antigen in Lung Neuroendocrine Tumors: Unraveling a Role in Clinical Practice. <i>Journal of Thoracic Oncology</i> , 2014, 9, 273-284.	1.1	162
121	Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1354-1362.	1.1	34
122	Peritoneal Malignant Mesothelioma Metastatic to Supraclavicular Lymph Nodes. <i>International Journal of Surgical Pathology</i> , 2014, 22, 552-554.	0.8	3
123	Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 61-68.	2.8	88
124	Unraveling Tumor Grading and Genomic Landscape in Lung Neuroendocrine Tumors. <i>Endocrine Pathology</i> , 2014, 25, 151-164.	9.0	44
125	Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported <i>EWSR1-NEUROG1</i> translocation. <i>Histopathology</i> , 2014, 64, 1014-1026.	2.9	19
126	Grading the neuroendocrine tumors of the lung: an evidence-based proposal. <i>Endocrine-Related Cancer</i> , 2014, 21, 1-16.	3.1	192

#	ARTICLE	IF	CITATIONS
127	Controversial issues and new discoveries in lung neuroendocrine tumors. <i>Diagnostic Histopathology</i> , 2014, 20, 392-397.	0.4	10
128	Thulium laser versus staplers for anatomic pulmonary resections with incomplete fissures: negative results of a randomized trial. <i>Tumori</i> , 2014, 100, 259-64.	1.1	6
129	Is the Pathologist Indispensable in Gastrointestinal Stromal Tumors and Neuroendocrine Tumors?. <i>The Journal of Oncopathology</i> , 2014, 2, 9-31.	0.1	0
130	Localised thoracic sarcomas: Outcome improvement over time at a single institution. <i>European Journal of Cancer</i> , 2013, 49, 2689-2697.	2.8	16
131	In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/differentiated liposarcomas. <i>Laboratory Investigation</i> , 2013, 93, 1232-1240.	3.7	17
132	Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex. <i>Neoplasia</i> , 2013, 15, 511-IN17.	5.3	44
133	Are two better than one? A novel double mutant KIT in GIST that responds to Imatinib. <i>Molecular Oncology</i> , 2013, 7, 756-762.	4.6	17
134	Subtyping Non-Small Cell Lung Cancer. <i>International Journal of Surgical Pathology</i> , 2013, 21, 326-336.	0.8	35
135	Biological insights into BRAF ^{V600} mutations in melanoma patient. <i>Oncology</i> , 2013, 2, e25594.	4.6	6
136	¹²⁵ I-Np63 (p40) Distribution Inside Lung Cancer. <i>International Journal of Surgical Pathology</i> , 2013, 21, 229-239.	0.8	51
137	Olfactory receptor 51E1 as a novel target for diagnosis in somatostatin receptor-negative lung carcinoids. <i>Journal of Molecular Endocrinology</i> , 2013, 51, 277-286.	2.5	48
138	CDKN2A and MC1R variants influence dermoscopic and confocal features of benign melanocytic lesions in multiple melanoma patients. <i>Experimental Dermatology</i> , 2013, 22, 411-416.	2.9	26
139	Lung Adenocarcinoma Patient Refractory to Gefitinib and Responsive to Crizotinib, with Concurrent Rare Mutation of the Epidermal Growth Factor Receptor (L861Q) and Increased ALK/MET/ROS1 Gene Copy Number. <i>Journal of Thoracic Oncology</i> , 2013, 8, e105-e106.	1.1	17
140	Succinate Dehydrogenase B Subunit Immunohistochemical Expression Predicts Aggressiveness in Well Differentiated Neuroendocrine Tumors of the Ileum. <i>Cancers</i> , 2012, 4, 808-820.	3.7	6
141	Annual or biennial CT screening versus observation in heavy smokers. <i>European Journal of Cancer Prevention</i> , 2012, 21, 308-315.	1.3	381
142	¹²⁵ I-Np63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit, Sparing-Material Approach. <i>Journal of Thoracic Oncology</i> , 2012, 7, 281-290.	1.1	126
143	Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. <i>Modern Pathology</i> , 2012, 25, 1574-1583.	5.5	206
144	Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. <i>Lung Cancer</i> , 2012, 77, 507-514.	2.0	64

#	ARTICLE	IF	CITATIONS
145	Pulmonary Resections: Cytostructural Effects of Different-Wavelength Lasers versus Electrocautery. <i>Tumori</i> , 2012, 98, 90-93.	1.1	9
146	p40 (Î ¹ Np63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. <i>Modern Pathology</i> , 2012, 25, 405-415.	5.5	343
147	Receptor tyrosine kinase pathway analysis sheds light on similarities between clearâ€cell sarcoma and metastatic melanoma. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 111-126.	2.8	22
148	A modified vimentin histological score helps recognize pulmonary sarcomatoid carcinoma in small biopsy samples. <i>Anticancer Research</i> , 2012, 32, 1463-73.	1.1	21
149	Pulmonary resections: cytostructural effects of different-wavelength lasers versus electrocautery. <i>Tumori</i> , 2012, 98, 90-3.	1.1	5
150	ecancermedalscience. <i>Ecancermedalscience</i> , 2011, 5, 201.	1.1	20
151	Heterogeneity of Large Cell Carcinoma of the Lung. <i>American Journal of Clinical Pathology</i> , 2011, 136, 773-782.	0.7	48
152	Unusual giant cell tumor of a floating rib: A case report. <i>Tumori</i> , 2011, 97, e34-e35.	1.1	0
153	The New Taxonomy of Lung Adenocarcinoma Stemming from a Multidisciplinary Integrated Approach: Novel Pathology Concepts and Perspectives. <i>Journal of Thoracic Oncology</i> , 2011, 6, 241-243.	1.1	9
154	miR-205 Expression Levels in Nonsmall Cell Lung Cancer Do Not Always Distinguish Adenocarcinomas From Squamous Cell Carcinomas. <i>American Journal of Surgical Pathology</i> , 2011, 35, 268-275.	3.7	47
155	Optimizing Pemetrexed-Gemcitabine Combination in Patients with Advanced Non-small Cell Lung Cancer: A Pharmacogenetic Approach. <i>Journal of Thoracic Oncology</i> , 2011, 6, 768-773.	1.1	14
156	Immunohistochemistry by Means of Widely Agreed-Upon Markers (Cytokeratins 5/6 and 7, p63, Thyroid) Tj ETQq0 0 0 rgBT /Overlock 10 Parallels the Corresponding Profiling and Eventual Diagnoses on Surgical Specimens. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1039-1049.	1.1	60
157	Screening-Detected Lung Cancers: Is Systematic Nodal Dissection Always Essential?. <i>Journal of Thoracic Oncology</i> , 2011, 6, 525-530.	1.1	43
158	Genomic characterization of asymptomatic CT-detected lung cancers. <i>Oncogene</i> , 2011, 30, 1117-1126.	5.9	7
159	Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors. <i>BMC Cancer</i> , 2011, 11, 351.	2.6	65
160	Chromosome 3p alterations in pancreatic endocrine neoplasia. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 39-45.	2.8	14
161	Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 497-503.	2.8	8
162	A serum circulating miRNA diagnostic test to identify asymptomatic highâ€risk individuals with early stage lung cancer. <i>EMBO Molecular Medicine</i> , 2011, 3, 495-503.	6.9	322

#	ARTICLE	IF	CITATIONS
163	Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology. <i>Cancer</i> , 2011, 117, 3416-3423.	4.1	124
164	Lung Cancer Risk Prediction to Select Smokers for Screening CT—a Model Based on the Italian COSMOS Trial. <i>Cancer Prevention Research</i> , 2011, 4, 1778-1789.	1.5	104
165	Intravascular Papillary Endothelial Hyperplasia of the Renal Vein. <i>International Journal of Surgical Pathology</i> , 2011, 19, 518-520.	0.8	8
166	Randomized Phase II Trial of Inhaled Budesonide versus Placebo in High-Risk Individuals with CT Screen-Detected Lung Nodules. <i>Cancer Prevention Research</i> , 2011, 4, 34-42.	1.5	52
167	ecancermedalscience. <i>Ecancermedalscience</i> , 2010, 4, 186.	1.1	12
168	Giant Alveolar Adenoma Causing Severe Dyspnoea. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1088-1090.	1.1	20
169	Review Article: Pulmonary Sarcomatoid Carcinomas: A Practical Overview. <i>International Journal of Surgical Pathology</i> , 2010, 18, 103-120.	0.8	144
170	Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. <i>Endocrine-Related Cancer</i> , 2010, 17, 977-987.	3.1	84
171	Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 clinically aggressive cases. <i>Annals of Oncology</i> , 2010, 21, 548-555.	1.2	144
172	Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. <i>Pharmacogenomics Journal</i> , 2010, 10, 180-190.	2.0	22
173	Structural lung damage after chemotherapy. <i>Lung Cancer</i> , 2010, 67, 306-310.	2.0	32
174	Study of Inorganic Particles, Fibers, and Asbestos Bodies by Variable Pressure Scanning Electron Microscopy with Annexed Energy Dispersive Spectroscopy and Micro-Raman Spectroscopy in Thin Sections of Lung and Pleural Plaque. <i>Applied Spectroscopy</i> , 2010, 64, 571-577.	2.2	22
175	The Classification of Lung Carcinoma: Time to Change the Morphology-Based Approach?. <i>International Journal of Surgical Pathology</i> , 2010, 18, 161-172.	0.8	23
176	A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer. <i>Acta Oncologica</i> , 2010, 49, 480-484.	1.8	12
177	A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma. <i>Acta Oncologica</i> , 2010, 49, 123-124.	1.8	3
178	Paraneoplastic Antigen Ma2 Autoantibodies as Specific Blood Biomarkers for Detection of Early Recurrence of Small Intestine Neuroendocrine Tumors. <i>PLoS ONE</i> , 2010, 5, e16010.	2.5	53
179	TNM Staging System of Colorectal Carcinoma: A Critical Appraisal of Challenging Issues. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 837-852.	2.5	147
180	Assessment of overdiagnosis in CT screening for lung cancer.. <i>Journal of Clinical Oncology</i> , 2010, 28, 1516-1516.	1.6	0

#	ARTICLE	IF	CITATIONS
181	Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung. <i>Anticancer Research</i> , 2010, 30, 4269-81.	1.1	32
182	Right pelvic mass in a patient with a radically resected carcinoid of the appendix. <i>Gut</i> , 2009, 58, 1200-1200.	12.1	0
183	Alterations of the Notch pathway in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 22293-22298.	7.1	350
184	Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non-Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments. <i>International Journal of Surgical Pathology</i> , 2009, 17, 206-218.	0.8	84
185	Randomized Biomarker Trial of Anastrozole or Low-Dose Tamoxifen or Their Combination in Subjects with Breast Intraepithelial Neoplasia. <i>Clinical Cancer Research</i> , 2009, 15, 7053-7060.	7.0	21
186	Morphology and a Limited Number of Immunohistochemical Markers May Efficiently Subtype Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, e141-e142.	1.6	41
187	Poorly differentiated synovial sarcoma of the vagina: A case report and a clinical literature review. <i>Eancermedicalsience</i> , 2009, 3, 99.	1.1	4
188	Randomized Double-Blind 2 × 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in High-Risk Premenopausal Women. <i>Journal of Clinical Oncology</i> , 2009, 27, 3749-3756.	1.6	98
189	Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. <i>Modern Pathology</i> , 2009, 22, 709-717.	5.5	91
190	Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor. <i>Oncogene</i> , 2009, 28, 2959-2968.	5.9	96
191	Tumor deposits are encountered in advanced colorectal cancer and other adenocarcinomas: an expanded classification with implications for colorectal cancer staging system including a unifying concept of in-transit metastases. <i>Modern Pathology</i> , 2009, 22, 410-415.	5.5	72
192	Erlotinib Combined with Cyclosporine in a Liver-Transplant Recipient with Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 138-139.	1.1	6
193	Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. <i>Human Mutation</i> , 2008, 29, 609-616.	2.5	72
194	Genetic alterations in combined neuroendocrine neoplasms of the lung. <i>Modern Pathology</i> , 2008, 21, 414-422.	5.5	25
195	Pericolonic tumour deposits in colorectal cancer patients: the challenge is on-going. <i>Histopathology</i> , 2008, 52, 767-768.	2.9	4
196	Differentiating neuroblastoma arising in mediastinal germ cell tumour. <i>Histopathology</i> , 2008, 53, 350-352.	2.9	5
197	Computer-assisted image analysis of breast fine needle aspiration in a randomized chemoprevention trial of fenretinide vs. placebo in HRT users. <i>Breast</i> , 2008, 17, 91-97.	2.2	1
198	Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 136, 611-617.	0.8	47

#	ARTICLE	IF	CITATIONS
199	Lung cancer screening with low-dose computed tomography: A non-invasive diagnostic protocol for baseline lung nodules. <i>Lung Cancer</i> , 2008, 61, 340-349.	2.0	166
200	Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: A baseline and 2-year repeat study. <i>Lung Cancer</i> , 2008, 62, 202-214.	2.0	25
201	Invited Commentary. <i>Annals of Thoracic Surgery</i> , 2008, 86, 1090-1091.	1.3	0
202	Imaging of Lung Hamartomas by Multidetector Computed Tomography and Positron Emission Tomography. <i>Annals of Thoracic Surgery</i> , 2008, 86, 1769-1772.	1.3	45
203	Colorectal Adenocarcinoma Spread Through Small Vessels. <i>International Journal of Surgical Pathology</i> , 2008, 16, 438-439.	0.8	1
204	Thyroid-Type Papillary Microcarcinoma in Ovarian Strumal Carcinoid. <i>International Journal of Surgical Pathology</i> , 2008, 16, 435-437.	0.8	12
205	Brief Report: Activity of Imatinib in a Patient with Platelet-Derived-Growth-Factor Receptor Positive Malignant Solitary Fibrous Tumor of the Pleura. <i>Journal of Thoracic Oncology</i> , 2008, 3, 938-941.	1.1	51
206	Morbidity and mortality after surgical treatment of screening detected lung cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 7531-7531.	1.6	1
207	Genomic characterization of early-stage asymptomatic lung cancers. <i>Journal of Clinical Oncology</i> , 2008, 26, 11106-11106.	1.6	1
208	Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users. <i>Journal of Clinical Oncology</i> , 2007, 25, 4201-4209.	1.6	64
209	Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression. <i>Carcinogenesis</i> , 2007, 28, 2082-2088.	2.8	74
210	Challenging Diagnosis of an Unusual Solitary Pulmonary Nodule. <i>Thoracic and Cardiovascular Surgeon</i> , 2007, 55, 123-125.	1.0	7
211	3q26 Amplification and Polysomy of Chromosome 3 in Squamous Cell Lesions of the Lung: A Fluorescence In situ Hybridization Study. <i>Clinical Cancer Research</i> , 2007, 13, 1995-2004.	7.0	28
212	Expression of p63 in Thymomas and Normal Thymus. <i>American Journal of Clinical Pathology</i> , 2007, 127, 415-420.	0.7	62
213	Benign Hyperplastic Mesothelial Cells in Lymph Node. <i>International Journal of Surgical Pathology</i> , 2007, 15, 297-299.	0.8	10
214	Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 131-134.	1.1	16
215	Invited commentary. <i>Annals of Thoracic Surgery</i> , 2007, 83, 214-215.	1.3	4
216	Role of Positron Emission Tomography Scanning in the Management of Lung Nodules Detected at Baseline Computed Tomography Screening. <i>Annals of Thoracic Surgery</i> , 2007, 84, 959-966.	1.3	72

#	ARTICLE	IF	CITATIONS
217	Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. <i>Digestive and Liver Disease</i> , 2007, 39, 537-543.	0.9	40
218	Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. <i>Prostate</i> , 2007, 67, 603-604.	2.3	17
219	Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. <i>British Journal of Cancer</i> , 2007, 96, 1118-1126.	6.4	45
220	Pathological assessment of pericolonic tumor deposits in advanced colonic carcinoma: relevance to prognosis and tumor staging. <i>Modern Pathology</i> , 2007, 20, 843-855.	5.5	108
221	Poorly differentiated synovial sarcoma of the vagina: first reported case with immunohistochemical, molecular and ultrastructural data. <i>Histopathology</i> , 2007, 50, 808-810.	2.9	23
222	Results of chest wall resection for recurrent or locally advanced breast malignancies. <i>Breast</i> , 2007, 16, 297-302.	2.2	45
223	Prognostic role of lymph node involvement in lung metastasectomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 133, 967-972.	0.8	60
224	Primary thoracic synovial sarcoma: Factors affecting long-term survival. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 134, 808-809.e1.	0.8	6
225	Induction of gemcitabine (GCB)-related genes by pemetrexed (MTA): Assessment of the best time interval between MTA and GCB administration. <i>Journal of Clinical Oncology</i> , 2007, 25, 14145-14145.	1.6	0
226	Results of annual screening of lung cancer with low dose computed tomography in 5,000 high-risk individuals. <i>Journal of Clinical Oncology</i> , 2007, 25, 7566-7566.	1.6	0
227	Treatment of pulmonary metastases from primary intraosseous odontogenic carcinoma. <i>Lancet Oncology</i> , 2006, 7, 272-273.	10.7	10
228	Large cell neuroendocrine carcinoma of the lung: A retrospective analysis of 144 surgical cases. <i>Lung Cancer</i> , 2006, 53, 111-115.	2.0	143
229	Salivary Gland-Type Tumors With Myoepithelial Differentiation Arising in Pulmonary Hamartoma. <i>American Journal of Surgical Pathology</i> , 2006, 30, 375-387.	3.7	21
230	Decreased Immunoreactivity of CD99 Is an Independent Predictor of Regional Lymph Node Metastases in Pulmonary Carcinoid Tumors. <i>Journal of Thoracic Oncology</i> , 2006, 1, 468-477.	1.1	6
231	Decreased Immunoreactivity of CD99 Is an Independent Predictor of Regional Lymph Node Metastases in Pulmonary Carcinoid Tumors. <i>Journal of Thoracic Oncology</i> , 2006, 1, 468-477.	1.1	6
232	Immunoreactivity for Sex Steroid Hormone Receptors in Pulmonary Hamartomas. <i>American Journal of Surgical Pathology</i> , 2006, 30, 819-827.	3.7	12
233	Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 98, 167-172.	2.5	7
234	Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 7-15.	2.8	17

#	ARTICLE	IF	CITATIONS
235	Subclavicular recurrence of breast cancer: Does surgery play a role?. <i>Breast</i> , 2006, 15, 649-653.	2.2	1
236	Superior vena cava replacement for lung cancer using a heterologous (bovine) prosthesis: Preliminary results. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2006, 131, 490-491.	0.8	36
237	Video-assisted management of malignant pleural effusion in breast carcinoma. <i>Cancer</i> , 2006, 106, 271-276.	4.1	29
238	Images in Pathology. <i>International Journal of Surgical Pathology</i> , 2006, 14, 73-74.	0.8	2
239	A Primary Pure Yolk Sac Tumor of the Lung Exhibiting CDX-2 Immunoreactivity and Increased Serum Levels of Alkaline Phosphatase Intestinal Isoenzyme. <i>International Journal of Surgical Pathology</i> , 2006, 14, 247-251.	0.8	35
240	Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma. <i>Acta Oncologica</i> , 2006, 45, 627-629.	1.8	7
241	Preliminary Results on Safety and Activity of a Randomized, Double-Blind, 2 × 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in Premenopausal Women. <i>Journal of Clinical Oncology</i> , 2006, 24, 129-135.	1.6	40
242	Erlotinib-Induced Breast Cancer Regression. <i>Annals of Pharmacotherapy</i> , 2006, 40, 2043-2047.	1.9	17
243	Histidine Decarboxylase, DOPA Decarboxylase, and Vesicular Monoamine Transporter 2 Expression in Neuroendocrine Tumors: Immunohistochemical Study and Gene Expression Analysis. <i>Journal of Histochemistry and Cytochemistry</i> , 2006, 54, 863-875.	2.5	42
244	Low dose spiral computed tomography for early diagnosis of lung cancer. Results of baseline screening in 5,000 high-risk volunteers. <i>Journal of Clinical Oncology</i> , 2006, 24, 7029-7029.	1.6	5
245	Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 50, 272-87.	0.7	20
246	Decreased immunoreactivity of CD99 is an independent predictor of regional lymph node metastases in pulmonary carcinoid tumors. <i>Journal of Thoracic Oncology</i> , 2006, 1, 468-77.	1.1	4
247	Typical and Atypical Pulmonary Carcinoid Tumor Overdiagnosed as Small-Cell Carcinoma on Biopsy Specimens. <i>American Journal of Surgical Pathology</i> , 2005, 29, 179-187.	3.7	226
248	Pulsed Dose-Rate Perioperative Interstitial Brachytherapy for Soft Tissue Sarcomas of the Extremities and Skeletal Muscles of the Trunk. <i>Annals of Surgical Oncology</i> , 2005, 12, 935-942.	1.5	17
249	Malignancy-associated X chromosome allelic losses in foregut endocrine neoplasms: further evidence from lung tumors. <i>Modern Pathology</i> , 2005, 18, 795-805.	5.5	20
250	Mediastinal-like growing teratoma syndrome. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 130, 228-229.	0.8	4
251	Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I nonsmall cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. <i>International Journal of Cancer</i> , 2005, 113, 101-108.	5.1	33
252	Alteration of the E-cadherin/?-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids. <i>Cancer</i> , 2005, 103, 1154-1164.	4.1	50

#	ARTICLE	IF	CITATIONS
253	A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear β -catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 447, 969-977.	2.8	15
254	Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 446, 604-612.	2.8	12
255	High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. <i>Annals of Oncology</i> , 2005, 16, 1133-1139.	1.2	43
256	Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2005, 97, 461-462.	6.3	3
257	Target-Treatment and Patients' Selection: Can We Still Neglect the Timing of Tissue Collection?. <i>Journal of Clinical Oncology</i> , 2005, 23, 6274-6275.	1.6	2
258	Immunohistochemical Detection of HER1/HER2 Can Be Considered a Predictive Marker of Gefitinib Activity in Non-Small-Cell Lung Cancer?. <i>Journal of Clinical Oncology</i> , 2005, 23, 921-922.	1.6	5
259	Jaw avascular bone necrosis associated with long-term use of biphosphonates. <i>Annals of Oncology</i> , 2005, 16, 1207-1208.	1.2	43
260	Langerhans' cell histiocytosis. <i>Lancet, The</i> , 2005, 365, 598.	13.7	2
261	Two-Year Survival After Multiple Bilateral Lung Metastasectomies for Cranial Meningioma. <i>Annals of Thoracic Surgery</i> , 2005, 80, 1129-1130.	1.3	13
262	Extended Pneumonectomy With Partial Resection of the Left Atrium, Without Cardiopulmonary Bypass, for Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2005, 79, 234-240.	1.3	77
263	Tumour CEA as predictor of better outcome in squamous cell carcinoma of the lung. <i>Lung Cancer</i> , 2005, 48, 233-240.	2.0	17
264	First-line gefitinib combined with simplified FOLFOX-6 in patients with epidermal growth factor receptor-positive advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 3659-3659.	1.6	12
265	Modulation of Epidermal Growth Factor Receptor Status by Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer Is Rare. <i>Journal of Clinical Oncology</i> , 2004, 22, 4966-4970.	1.6	31
266	Lung Cancers Detected by Screening with Spiral Computed Tomography Have a Malignant Phenotype when Analyzed by cDNA Microarray. <i>Clinical Cancer Research</i> , 2004, 10, 6023-6028.	7.0	64
267	Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial. <i>Clinical Cancer Research</i> , 2004, 10, 2336-2343.	7.0	182
268	K-ras gene mutational analysis supports a monoclonal origin of biphasic pleomorphic carcinoma of the lung. <i>Modern Pathology</i> , 2004, 17, 538-546.	5.5	54
269	CD117 immunoreactivity in stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients. <i>Modern Pathology</i> , 2004, 17, 711-721.	5.5	46
270	CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 445, 449-455.	2.8	51

#	ARTICLE	IF	CITATIONS
271	Detecting lung cancer in plasma with the use of multiple genetic markers. <i>International Journal of Cancer</i> , 2004, 108, 91-96.	5.1	78
272	CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 443, 782-786.	2.8	73
273	Fluorodeoxyglucose positron emission tomography improves preoperative staging of resectable lung metastasis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 126, 1906-1910.	0.8	77
274	Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma. <i>Cancer</i> , 2003, 97, 2487-2497.	4.1	96
275	Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group. <i>British Journal of Cancer</i> , 2003, 88, 645-647.	6.4	11
276	Microallelotyping Defines the Monoclonal or the Polyclonal Origin of Mixed and Collision Endocrine-Exocrine Tumors of the Gut. <i>Laboratory Investigation</i> , 2003, 83, 963-971.	3.7	96
277	Quantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 3902-3908.	1.6	510
278	Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. <i>Lung Cancer</i> , 2003, 42, 203-213.	2.0	83
279	Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. <i>Lancet, The</i> , 2003, 362, 593-597.	13.7	422
280	Persistent excess mortality from lung cancer in patients with stage I non-small-cell lung cancer, disease-free after 5 years. <i>British Journal of Cancer</i> , 2003, 88, 1666-1668.	6.4	21
281	Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. <i>British Journal of Cancer</i> , 2003, 88, 537-547.	6.4	169
282	Synchronous bilateral lung carcinoid tumors: a rare entity?. <i>European Journal of Cardio-thoracic Surgery</i> , 2003, 24, 334.	1.4	8
283	A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers. <i>Journal of the National Cancer Institute</i> , 2003, 95, 779-790.	6.3	190
284	T Cells in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2003, 348, 1814-1814.	27.0	1
285	Pleomorphic Carcinomas of the Lung Show a Selective Distribution of Gene Products Involved in Cell Differentiation, Cell Cycle Control, Tumor Growth, and Tumor Cell Motility. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1203-1215.	3.7	86
286	Bronchioloalveolar Carcinoma. <i>New England Journal of Medicine</i> , 2002, 346, 1671-1672.	27.0	0
287	Low morbidity of bronchoplastic procedures after chemotherapy for lung cancer. <i>Lung Cancer</i> , 2002, 36, 91-97.	2.0	48
288	Late events and clinical prognostic factors in stage I non small cell lung cancer. <i>Lung Cancer</i> , 2002, 37, 171-177.	2.0	21

#	ARTICLE	IF	CITATIONS
289	High-dose Chemotherapy in Small Cell Lung Cancer. <i>Tumori</i> , 2002, 88, 179-186.	1.1	4
290	Progesterone receptor immunoreactivity in minute meningothelioid nodules of the lung. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 440, 543-546.	2.8	31
291	p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?. <i>Journal of Pathology</i> , 2002, 198, 100-109.	4.5	134
292	The presence of bone marrow cytokeratin-immunoreactive cells does not predict outcome in gastric cancer patients. <i>British Journal of Cancer</i> , 2002, 86, 1047-1051.	6.4	20
293	Fluoro-deoxy-glucose uptake and angiogenesis are independent biological features in lung metastases. <i>British Journal of Cancer</i> , 2002, 86, 1391-1395.	6.4	21
294	Epithelial-Myoepithelial Carcinomas of the Bronchus. <i>American Journal of Surgical Pathology</i> , 2002, 26, 950-951.	3.7	3
295	Immunoreactivity for Thyroid Transcription Factor-1 in Stage I Non-Small Cell Carcinomas of the Lung. <i>American Journal of Surgical Pathology</i> , 2001, 25, 363-372.	3.7	174
296	Pulmonary Epithelial-Myoepithelial Tumor of Unproven Malignant Potential: Report of a Case and Review of the Literature. <i>Modern Pathology</i> , 2001, 14, 521-526.	5.5	65
297	CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000, 437, 270-274.	2.8	41
298	Early hilar lung cancer "clinical aspects and long term survival. Identification of a subgroup of stage IA patients with more favorable prognosis. <i>Lung Cancer</i> , 2000, 27, 119-124.	2.0	17
299	Effects of Different Immunolabeling Techniques on the Detection of Small-cell Lung Cancer Cells in Bone Marrow. <i>Journal of Histochemistry and Cytochemistry</i> , 1999, 47, 1075-1088.	2.5	8
300	Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients. <i>British Journal of Cancer</i> , 1999, 81, 1213-1221.	6.4	12
301	Bone marrow micrometastases in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1999, 58, 123-130.	2.5	22
302	TIPS allowing for an endoscopic mucosal resection of early gastric cancer in a cirrhotic patient with severe hypertensive gastropathy: Report of a case. <i>Surgery Today</i> , 1999, 29, 902-905.	1.5	12
303	Classification of Lymph Node Metastases from Carcinoma of the Stomach: Comparison of the Old (1987) and New (1997) TNM Systems. <i>World Journal of Surgery</i> , 1999, 23, 664-669.	1.6	37
304	Incidence and Prognostic Value of Bone Marrow Involvement in Small Cell Lung Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 1999, 7, 21-28.	1.2	0
305	Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. <i>Journal of Pathology</i> , 1998, 186, 41-50.	4.5	70
306	Does bone marrow involvement affect prognosis in small-cell lung cancer?. <i>Annals of Oncology</i> , 1998, 9, 247-250.	1.2	10

#	ARTICLE	IF	CITATIONS
307	Study on Ki-67 Immunoreactivity as a Prognostic Indicator in Patients with Advanced Gastric Cancer. Japanese Journal of Clinical Oncology, 1998, 28, 534-537.	1.3	33
308	Prognostic Significance of 67-kDa Laminin Receptor Expression in Advanced Gastric Cancer. Oncology, 1998, 55, 456-460.	1.9	34
309	Positive immunostaining with MLuC1 of bone marrow aspirate predicts poor outcome in patients with small-cell lung cancer. Annals of Oncology, 1998, 9, 181-185.	1.2	9
310	Bone marrow micrometastases in 109 breast cancer patients: Correlations with clinical and pathological features and prognosis. Breast Cancer Research and Treatment, 1997, 42, 23-30.	2.5	67
311	High-affinity monomeric 67-kd laminin receptors and prognosis in pancreatic endocrine tumours. , 1997, 183, 62-69.		52
312	Ki-67 immunostaining in 322 primary breast cancers: Associations with clinical and pathological variables and prognosis. International Journal of Cancer, 1997, 74, 433-437.	5.1	96
313	Immunodetection of Breast Cancer Cells in Bone Marrow for Monitoring High-dose Sequential Chemotherapy. Applied Immunohistochemistry & Molecular Morphology, 1997, 5, 67-70.	2.0	3
314	Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: A comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Human Pathology, 1996, 27, 1124-1134.	2.0	251
315	Proliferation markers and their uses in the study of endocrine tumors. Endocrine Pathology, 1996, 7, 103-119.	9.0	24
316	Fat body of the frog <i>Rana esculenta</i> : An ultrastructural study. , 1996, 227, 321-334.		9
317	Solid and cystic papillary neoplasm of the pancreas: A clinico-cytopathologic and immunocytochemical study of five new cases diagnosed by fine-needle aspiration cytology and a review of the literature. Diagnostic Cytopathology, 1995, 13, 233-246.	1.0	59
318	Estrogen receptors in 699 primary breast cancers: A comparison of immunohistochemical and biochemical methods. Breast Cancer Research and Treatment, 1995, 34, 221-228.	2.5	34
319	Detection at diagnosis of tumor cells in bone marrow aspirates of patients with small-cell lung cancer (SCLC) and clinical correlations. Annals of Oncology, 1995, 6, 86-88.	1.2	11
320	pTNM Stage Distribution in Breast Cancer: A Population-Based Survey in Northern Italy. Tumori, 1994, 80, 263-268.	1.1	0
321	Methodological aspects of the immunostaining of proliferating cell nuclear antigen (PCNA) in cytospin preparations of MCF-7 cell line. Diagnostic Cytopathology, 1994, 10, 82-85.	1.0	3
322	Expression of proliferating cell nuclear antigen, Ki-67 antigen, estrogen receptor protein, and tumor suppressor p53 gene in cytologic samples of breast cancer: An immunochemical study with clinical, pathobiological, and histologic correlations. Diagnostic Cytopathology, 1994, 11, 131-140.	1.0	32
323	Detection of the neural cell adhesion molecule (NCAM) in serum of patients with small-cell lung cancer (SCLC) with limited or extensive disease, and bone-marrow infiltration. International Journal of Cancer, 1994, 57, 49-52.	5.1	29
324	Detection of small-cell-lung-cancer cells in bone-marrow aspirates by monoclonal antibodies NCC-LU-243, NCC-LU-246 and MLuCl. International Journal of Cancer, 1994, 57, 53-56.	5.1	9

#	ARTICLE	IF	CITATIONS
325	Immunohistochemical identification of the uncoupling protein in human hibernoma. <i>Biology of the Cell</i> , 1994, 80, 75-78.	2.0	27
326	Immunocytochemical detection of cell proliferation-related antigens in cytologic smears of human malignant neoplasms using PC10, reactive with proliferating cell nuclear antigen, and Ki-67. A comparative study. <i>Archives of Pathology and Laboratory Medicine</i> , 1994, 118, 510-6.	2.5	11
327	Expression of progesterone receptors in solid-cystic tumour of the pancreas. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1993, 423, 425-431.	1.4	87
328	Immunodetection of Proliferating Cell Nuclear Antigen Assesses the Growth Fraction and Predicts Malignancy in Endocrine Tumors of the Pancreas. <i>American Journal of Surgical Pathology</i> , 1992, 16, 1215-1225.	3.7	82
329	A comparative analysis of three different techniques for the detection of breast cancer cells in bone marrow. <i>Cancer</i> , 1991, 67, 1033-1036.	4.1	78
330	Peripheral giant cell granuloma: Evidence for osteoclastic differentiation. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1990, 70, 471-475.	0.6	47
331	Isomerism of the left atrial appendages associated with absence of the spleen. <i>International Journal of Cardiology</i> , 1990, 27, 380-382.	1.7	1
332	Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	12